Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3611 - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.


30 Sep 2019


Poster Display session 3


Tumour Site

Prostate Cancer


Benjamin Gartrell


Annals of Oncology (2019) 30 (suppl_5): v325-v355. 10.1093/annonc/mdz248


B. Gartrell1, G. Del Priore2, A. Retter3, W. Chen4, G.H. Sokol5, A. Vandell6, M. Roach7, H.I. Scher8

Author affiliations

  • 1 Oncology, Montefiore Medical Center, 10461 - New York/US
  • 2 Cmo, Tyme Inc, 10004 - New York/US
  • 3 Oncology, Eastchester Cancer Care Center, 10469 - New York/US
  • 4 Oncology, Vitatex, 11794 - Stony Brook/US
  • 5 Oncology, Florida Cancer Specialist, 34667 - Florida/US
  • 6 Clinical Research, Tyme Inc., 10004 - New York/US
  • 7 Radiation Oncology/urology, UCSF, 94143 - San Francisco/US
  • 8 Medicine, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3611


Androgen deprivation therapy (ADT) is standard treatment for rising PSA with/without circulating tumor cells (CTCs) but adverse events (AEs) limit patient acceptance. We report results of SM-88 (D,L-alpha-metyrosine; racemetyrosine [USAN]) in combination with a CYP3A4 inducer, mTOR inhibitor and catalyst that does not lower testosterone (T).


Phase 2 with a rising PSA (per PCWG3), no disease on imaging and detectable CTCs.


From Sept 2016-April 2019, 35 subjects consented; 23 evaluable (completed >1 cycle); 60.9% were post RT. Mean age 70.6; BMI 28.9; 21.7% black. Mean T rose (319.1 to 346.0 ng/dL p = 0.08) over 12 weeks. Subjects did not report side effects commonly associated with hormone suppression. Assessments of EORTC measured domains sexual health, overall health, and quality of life remained stable, with depression, hot flushes, and enlarged breast reported as “Not at all” (remained at 1). There was no detectable worsening in any domain of EORTC QLQ-C30 or QLQ-PR25. No clinically significant changes were seen in weight, hct, glu, urinary N telopeptide, MAP (in normotensives and hypertensives), heart rate, Ca ++, LDH, bsAlkPhos, triglycerides, albumin, or QTc. NLR decreased at the end of cycle 1 in 75% of those with radiographic and/or PSA progression vs 53% of those who did not. 15/23 (65.2%) subjects reported experiencing an AE. 1 unrelated Grade 3; 18/35 (51.4%) at least possibly related to drug. No AEs were related to T levels. There were no skeletal or cardiovascular events. From initial diagnosis of PSA rise 100% (23/23) remained metastases free. PSA declined (4% 1/23) stabilized (83% 19/23) or rose (13% 3/23). 56.5% (13/23) subjects experienced an improvement in median PSA DT. Median DT time improved from 6.2 to 8.0 months for all subjects completing 3 cycles of therapy. CTCs were > 5 in 100% at baseline. After 12 weeks, there was a 65.3% (-100% to -8.8%) median CTC decrease from baseline (n = 18), with all subjects having CTC counts below baseline and 2 undetectable.


SM-88 may delay the start of HT and be useful when normal T is preferred. QOL was maintained without ADT AEs. Favorable effects on PSA and CTCs kinetics were observed consistent with a favorable treatment effect. Trials to confirm these benefits are planned.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Tyme Inc.


Tyme Inc.


G. Del Priore: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Tyme Inc. G.H. Sokol: Advisory / Consultancy: Tyme Inc. A. Vandell: Full / Part-time employment: Tyme Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.